IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 144.9

Change

0.00 (0.00)%

Market Cap

USD 7.60B

Volume

1.20M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Health

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

N/A

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.45% 25% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.45% 25% F 9% A-
Trailing 12 Months  
Capital Gain -60.50% 25% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.50% 25% F 11% F
Trailing 5 Years  
Capital Gain -51.46% 25% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.46% 25% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 3.53% N/A N/A 53% F
Dividend Return 3.76% N/A N/A 50% F
Total Return 0.24% N/A N/A 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 20.02% N/A N/A 76% C+
Risk Adjusted Return 18.78% N/A N/A 53% F
Market Capitalization 7.60B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike